Table 1.
Organ | Human disease | Editing strategy | Disease model | Administration | Ref. |
---|---|---|---|---|---|
Eye | Retinitis pigmentosa, autosomal recessive, PDE6B mutation | SpCas9/RecA mediated HDR | Pde6b Y347X, nonsense mutation mice | SpCas9, sgRNA, RecA-MS2 Plasmid and ssDNA donor, subretinal and electroporation | 244 |
Retinitis pigmentosa, autosomal dominant • P23H mutation (class 2) • Class 1 |
Knockdown Rho | Rho-P23H transgenic mice | Cas9-sgRNA plasmids, subretinal and electroporation | 245 | |
Knockdown mutant Rho | Rho-P23H heterozygous mice | SpCas9-VRQR plasmid and sgRNA plasmid, subretinal and electroporation | 143 | ||
Rho S334ter rat | Cas9-sgRNA plasmid, subretinal and electroporation | 141 | |||
Knockdown of transcription factor Neural Leuzine zipper (Nrl) | Rho−/−, Rd10, Rho-P347S mice | AAV8-RK-SpCas9, AAV-sgRNA, subretinal | 246 | ||
LCA, autosomal recessive • Type 10, IVS26 mutation in CEP20 • Type 2, RPE65 mutation |
NHEJ in-frame indels or HR | Humanized CEP290 IVS26 knock-in mice, NHP | AAV5-sgRNA-GRK1-SaCas9, subretinal | 222 | |
Rpe65 nonsense mutation rd12 mice | AAV9-EFS-SpCas9, AAV9-sgRNA-Rpe65-donor, subretinal | 247 | |||
Meesman epithelial corneal dystrophy, dominant negative, KRT12 mutation | Knockdown, allele specific, Deplete mutant KRT12 | KRT12-L132P humanized heterozygous mice | SpCas9 and sgRNA plasmids, Intrastromal ocular | 142 | |
Neovascular age-related macular degeneration | Knockdown, NHEJ mediated disruption of Vegfa or Hif1a | Laser-induced choroidal neovascularization in mouse eyes | AAV8-CMV-SpCas9, AAV8-sgRNA, subretinal | 146 | |
AAV9-EFS-LbCpf1-crRNA, intravitreal | 248 | ||||
Neurological | Huntington's disease (CAG trinucelotide), expansion mutant HTT | Knockdown HTT | HD140Q-knock-in mice, human HTT exon 1 with 140 CAG repeats (homozygous and heterozygous) | AAV-MECP2-Cas9, AAV-gRNA, intracranial | 249 |
Knockdown mutant HTT | R6/2 mice, transgenic mice, human HTT exon 1 with 115–150 CAG repeats | AAV1-hSyn-SaCas9-sgRNA, intracranial | 196 | ||
ALS, autosomal dominant, SOD1 mutations | Knockdown human SOD1 | Transgenic human SOD1 G93A mutation ALS neonatal mice | AAV9-CMV-SaCas9-sgRNA, intravenous or intracerebroventricular | 193,194 | |
BE3 disruption of SOD1 | AAV9-CAG-N-Int-CBE-U6-sgRNA, AAV9-CAG-C-Int-CBE-U6-sgRNA, inthrathecal | 195 | |||
Fragile X syndrome | Knockdown GRM5 | Fmr1 KO mice, FXS mice model | CRISPR Gold nanoparticle Cas9 RNP and donor DNA, intracranial | 82 | |
Alzheimer's disease | Knockdown Bace1 | Five familial Alzheimer's disease transgenic mice, APP knock-in Alzheimer's disease mice | Amphiplilic R7L10 peptide nanocomplex Cas9 RNP, intracranial | 7 | |
Dravet Syndrome, haploinsufficiency, SCN1A loss of function mutation | dCas9-Vp64 mediated Scn1a gene activation (both WT and mutant) | Scn1a heterozygous Dravet Syndrome mice | AAV9-dCas9-VP64, AAV9-sgRNA, intracerebroventricular | 250 | |
Severe obesity, haploinsufficiency, SIM1 or MC4R | dCas9-Vp64 mediated gene activation of Sim1 | Sim1/Mc4r heterozygous mice | AAVDJ-CMV-dCas9-Vp64, AAVDJ-sgRNA, hypothalamic | 251 | |
Liver | Hemophilia B, X-linked recessive | HDR, insert hFIX-padua exon 2–8 in mFIX exon 2 | FIX Knockout mice | AAV8-Cas9, AAV8-sgRNA-Donor DNA | 165 |
HDR, insert into mFIX into murine ROSA26 safe harbor | R333Q Hemophilia mice | Ad5-Cas9-gRNA, Ad5-EF1α-mFIX, intravenous | 252 | ||
Hemophilia B, Y371D mutation in FIX | HDR | Y381D Hemophilia B mice | Naked DNA, SpCas9, ssODN-HDR Donor, intravenous | 253 | |
Hemophilia A, X-linked recessive | Insert human B-domain deleted FVIII in intron 13 of liver-specific albumin locus | FVIII Knockout mice | AAV8-SaCas9-sgRNA, AAV8-donor DNA | 166 | |
OTC deficiency, X-linked recessive | HDR, correct point mutation | spf/ash heterozygous OTC neonate mice | AAV8-TBG-SaCas9, AAV8-sgRNA-donor DNA, intravenous | 168 | |
HDR, insert codon-optimized human OTC into intron 4 of mouse OTC locus | AAV8-TBG-SaCas9, AAV8-sgRNA-TBG-hOTCco, intravenous injection | 167 | |||
Hypercholesteolemia | BE3, disruption of mouse W159 Pcsk9 | WT C57BL/6 mice | Ad-BE3-sgRNA, retro-orbital | 242 | |
BE3, disruption of human W159 PCSK10 or NHEJ-mediated disruption of PCSK10 | Humanized PCSK9 knock-in mice | Ad5-Cas9-sgRNA or Ad5-BE3-sgRNA, Intravenous | 243 | ||
Atherogenic dyslipidemia, homozygous familial hypercholesterolemia | BE3, disruption of Q135 Angptl3 | Hyperlipidemic Ldlr-knockout mice | Ad-BE3-sgRNA | 254 | |
Phenylketonuria, autosomal recessive | BE3 | Homozygous point mutation in Pah-F263S, hyperphenylalaninemia mice | AAV8.N-int-BE3 and AAV8.C-int-BE3, intravenous | 255 | |
Hereditary tyrosinemia type I, autosomal recessive, FAH loss of function mutation | HDR | Fah homozygous mutation in exon 8 mice | SpCas9 mRNA by LNP and AAV8-sgRNA-donor template, intravenous | 78 | |
HDR with nCas9 | Homozygous 10-bp deletion in exon 2 of Fah in rat HTI model | Ad-nCas9 and Ad-donor template, intravenous | 256 | ||
Base editing, ABE6.3, tRNA nCas9-adenosine deaminase | Fah homozygous mutation in exon 8 mice | Plasmid by hydrodynamic injection or mRNA/sgRNA by LNP, intravenous | 257 | ||
Hereditary tyrosinemia type I, autosomal recessive, compound heterozygous mutations in FAH | Allelic exchange by targeting intron 7, NHEJ | compound heterozygous exon 5 insertion/exon 8 mutation in Fah, HTI mouse model | AAV9-SpCas9 and scAAV-sgRNA, intravenous | 258 | |
Muscle | DMD, exon 50 | Reframing or Exon skipping | ΔEx50 C57/BL6J mice | AAV9-CK8-SpCas9 and AAV9-sgRNA-51, intraperitoneal | 259 |
ΔEx50 dogs | AAV9-CK8-SpCas9 and AAV9-sgRNA-51, intravenous | 125 | |||
DMD, exon 44 | Reframing or Exon skipping | ΔEx44 C57BL/6 mice | AAV9-CK8-SpCas9 and AAV9-sgRNA, intraperitoneal | 260 | |
AAV9-CK8-SpCas9 and scAAV-sgRNA |
126 | ||||
DMD, exons 45–55 | Excise exon 52 and 53 | mdx4cw mice, nonsense mutation in exon 53 | AAV6-CK8-SpCas9 and AAV6-sgRNA or AAV6-CK8-SaCas9-sgRNA, retro-orbital | 120 | |
DMD, nonsense mutation in exon 23 | Excise exon 23 | Mdx mice, pt mutation in exon 23 | AAV9-CMV-SaCas9 and AAV9-sgRNA | 119 | |
AAV8-CMV-SaCas9 and AAV8-sgRNA, Intravenous | 124,261 | ||||
AAV9-CMV-SaCas9 and AAV9-sgRNA, intravenous | 262 | ||||
AAV9-miniCMV-spCas9 and AAV9-sgRNA, intraperitoneal | 263 | ||||
Excise exon 21–23 | Ad-Cas9-sgRNA | 264 | |||
HDR | CRISPR Gold nanoparticle Cas9 RNP and donor DNA, intramuscular | 80 | |||
NHEJ, indels to result in reframing | DMD KO C57/BL6J mice, ΔEx23 | AAV9-Spc5-12-CjCas9-sgRNA, intramuscular | 265 | ||
Wolff-Parkinson-White syndrome, autosomal dominant inherited disease, H530R mutation in PRKAG2 | Disrupt mutant allele | Heart specific H530R transgenic mice, Heterogeneous H530R PRKAG2 knock-in mice | AAV9-Cas9, scAAV9-sgRNA, intravenous or intraventricular | 8 | |
Ear | Dominant progressive hearing loss (DFN36), TMC1 | Knockdown mutant Tmc1 | Beethoven mice, heterozygous missense mutation in Tmc1 | Cas9-sgRNA RNP, cationic lipid complex, inner ear | 266 |
Anc80L65-CMV-SaCas9-sgRNA, inner ear | 267 | ||||
Multiorgan | MPS type I, autosomal recessive | HDR, insert Idua into murine ROSA26 safe harbor | Idua-knock-out MPS I mice | PrecisionX CRISPR/Cas9 SmartNuclease™, Idua donor vector, cationic liposomes, intravenous | 182 |
AAV, adeno-associated virus; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; Bace1, beta-secretase 1; DMD, Duchenne muscular dystrophy; FIX, factor IX; IDUA, α-l-iduronidase; LCA, Leber congenital amaurosis; LNP, lipid nanoparticle; MPS, mucopolysaccharidosis; NHEJ, nonhomologous end-joining; NHP, nonhuman primate; OTC, ornithine transcarbamylase; RNP, ribonucleoprotein; scAAV, self-complementary AAV.